Editorial
Targeting the adipose tissue to fight prostate cancer
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S229-S231
.
(16 July 2019)
Salvage prostate brachytherapy after definitive external radiation: tried and now tested
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S232-S235
.
(16 July 2019)
Biomarkers for platinum sensitivity in bladder cancer: are we there yet?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S236-S239
.
(16 July 2019)
Role of heat shock proteins in bladder cancer: potential biomarkers for treatment response and oncological prognosis
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S240-S241
.
(16 July 2019)
Adipose tissue: enabler of prostate cancer aggressive behavior
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S242-S245
.
(16 July 2019)
Dietary intake and prostate cancer, continued pursuit for evidence
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S246-S249
.
(16 July 2019)
Coping with chemoresistance in prostate cancer—co-targeting of adipose stromal cells?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S250-S253
.
(16 July 2019)
A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S254-S256
.
(16 July 2019)
Editorial Commentary
Long term results of the NRG/RTOG 9413: a key study but one of the most confusing study in prostate cancer radiotherapy!
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S257-S260
.
(16 July 2019)
Association between perioperative morbidity and mortality after radical cystectomy: an opportunity to understand the complication snowball effect
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S261-S262
.
(16 July 2019)
Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S263-S264
.
(16 July 2019)
Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526)
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S265-S270
.
(16 July 2019)
Experience of surgeon, hospital, and comprehensive cancer team critical to the outcomes of radical cystectomy and urinary diversion
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S271-S273
.
(16 July 2019)
Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S274-S276
.
(16 July 2019)
The clinical and economic burden of perioperative complications of radical cystectomy
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S277-S279
.
(16 July 2019)
Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S280-S282
.
(16 July 2019)
Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S283-S286
.
(16 July 2019)
Changes in testosterone prescribing patterns after FDA warning
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S287-S288
.
(16 July 2019)
Perioperative mortality following radical cystectomy: the slippery slope of complications
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S289-S290
.
(16 July 2019)
Prognostic impact of tumor infiltrating lymphocytes in bladder urothelial carcinoma
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S291-S292
.
(16 July 2019)
Molecular subtypes and response to immunotherapy in bladder cancer patients
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S293-S295
.
(16 July 2019)
Editorial: assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer, a prospective single arm clinical study: California shows the way!
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S296-S299
.
(16 July 2019)
Bladder organoids: a step towards personalised cancer therapy?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S300-S302
.
(16 July 2019)
The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S303-S306
.
(16 July 2019)
Editorial: early PSA-testing after radical prostatectomy—the truth behind the scenes
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S307-S309
.
(16 July 2019)
Establishing and characterization of human and murine bladder cancer organoids
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S310-S313
.
(16 July 2019)
Studying the impact of comorbidity on post radical cystectomy survival: have we come a full circle?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S314-S317
.
(16 July 2019)
The diagnosis of bladder cancer: are we missing a teachable moment for smoking cessation?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S318-S321
.
(16 July 2019)
Looking into the clinical application of CD47-targeted near-infrared photoimmunotherapy for human bladder cancer treatment
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S322-S324
.
(16 July 2019)
Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S325-S328
.
(16 July 2019)
How to guide the selection of patients for trimodality therapy: the case for tumor immune and stromal signature
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S329-S331
.
(16 July 2019)
Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S332-S334
.
(16 July 2019)
Prognosis in high-grade T1 bladder cancer: host immune response and tumour infiltrating lymphocytes
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S335-S336
.
(16 July 2019)
The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S337-S340
.
(16 July 2019)
Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S341-S345
.
(16 July 2019)
Letter to the Editor
An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S346-S347
.
(16 July 2019)
The role of adipose stroma in prostate cancer aggressiveness
Translational Andrology and Urology
2019;
8
(Suppl 3)
:S348-S350
.
(16 July 2019)
Disclosure:
The supplement was published without any sponsorship or funding.
